Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
109 results
D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab
D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis
D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic
D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates
D1.390 - Long-term safety and efficacy of navenibart in participants with hereditary angioedema (HAE): Initial combined results from ALPHA-STAR and ALPHA-SOLAR
D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab
D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results
D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years
D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center
D1.371 - Dupilumab for the treatment of refractory severe chronic spontaneous urticaria
000734 - A Systematic Review of Multidimensional Predictors for Refractory Chronic Rhinosinusitis
000773 - Stratification Value of Nasal Brushing Arachidonate 15-Lipoxygenase in Stapokibart (CM310) Treatment for Patients with Seasonal Allergic Rhinitis: Results from MERAK
000788 - Efficacy of Omalizumab in Refractory Chronic Rhinosinusitis with Nasal Polyps and Association with Local Immunoglobulin E
D1.156 - Early Immunologic Parameters Predicting Response to Sublingual Immunotherapy in Allergic Rhinitis Patients
D1.18 - Comparative Analysis of Nasal Secretions and Serum Biomarkers in House Dust Mite Allergy: Correlation with Symptoms and Skin Prick Test Results
D2.347 - Allergen-Specific T Cells to House Dust Mite are absent on the circulation of local allergic rhinitis patients
- D3.112 - Role of nasal cytology in patients with bronchial asthma
D3.137 - Effectiveness of Dupilumab in improving Quality of Life in patients with "steroid-resistant" asthma and severe atopic dermatitis
D3.140 - Xiaoqinglong Decoction Combined with Yupingfeng Powder Alleviates Allergic Rhinitis Complicated with Asthma by Inhibiting B Lymphocyte Activation via JAK2/STAT1/MHC-II signaling pathway
D3.197 - When is molecular testing necessary? Rethinking allergy diagnostics for Dermatophagoides pteronyssinus
Pagination
First page
First
Previous page
Previous
Page
1
Page
2
Page
3
Page
4
Current page
5
Page
6
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download